https://www.selleckchem.com/pr....oducts/CP-690550.htm
To analyze the efficacy and safety of duloxetine and gabapentin in painful diabetic neuropathy (PDN). A randomized, open-label, active control, 12-week trial was conducted. A total of 86 participants were randomized in 11 ratio into gabapentin 300 mg and duloxetine 60 mg groups. The primary efficacy objective was comparison of mean change in Visual Analogue Scale (VAS) (0-100 points) scores between duloxetine and gabapentin. The symptom scores and adverse events were assessed as secondary outcomes. Statistically significant (P value&l
Like
Comment
Share
